OCREVUS, a treatment for multiple sclerosis (MS), showed strong sales growth of 9% in 2025, reaching about $7.6 billion globally. Its broad efficacy in treating both relapsing and progressive MS, along with the recent approval of a convenient subcutaneous injection, has expanded patient access and sustained prescription momentum. Despite competition from biosimilars, OCREVUS remains a key growth driver for Roche, supported by robust clinical data and ongoing research. Market forecasts predict continued growth through 2034 across major regions including the US, Europe, and Japan.
Sampo Oyj will publish its financial results for the first nine months of 2026 on November 4, 2026, at around 8:30 AM. Alongside the report, supplementary presentation materials will be available on their website. An investor conference call will be ...
Alvotech, a global biotech company specializing in biosimilars, will release its financial results for the first nine months of 2026 on November 11 after U.S. market close. A live webcast presentation is scheduled for November 12 at noon, where manag...
Alvotech, a global biotech company specializing in biosimilars, announced it will report its financial results for the nine months and third quarter ending September 30, 2026, on November 11 after U.S. market close. The company will host a webcast wi...
Stella-Jones Inc. announced that its CEO Eric Vachon and CFO Silvana Travaglini will participate in the RBC Capital Markets 2026 Global Industrials Conference in New York on November 16, 2026. The company will hold meetings with institutional investo...
Xunce has launched TokenRouters, a platform designed as a one-stop hub for exchanging AI data and specialized tokens to optimize enterprise AI models. The platform addresses the challenge of matching AI resources by integrating datasets, models, appl...
